Teva Cracks The Door To Change With Promise To Shake Up Board
This article was originally published in The Pink Sheet Daily
The board of directors at Teva signaled a willingness to make important changes that could help mend ties between directors, management and investors by vowing to decrease the size of the board and welcome more experienced pharma directors.
You may also be interested in...
The US FDA appears to have concerns about the device used to administer the vaccine.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.